Oct 20, 2022 09:16 PM (GMT+8) · EqualOcean
Recently, BS Biotech (Chinese: 百盛生物) announced that it had completed a pre-Series A financing round worth CNY 10 million, which was jointly invested by Zhongda Venture Capital and Yanghe Investment. This financing round will be mainly used to promote the market development of pathological diagnosis products and the research and development of subsequent product pipelines. Founded in December 2018, BS Biotech focuses on providing the whole industry chain products and services of pathological diagnosis, including tissue morphology, immunohistochemistry, molecular diagnosis, etc.